Expansion of European business development team supports next phase of growth for Metrion’s ion channel drug discovery services
News
KISS Communications announced today its merger with digital agency Isle Interactive, adding
significant resources and strengthening its position as a leading creative agency.
The merger gives the award-winning agency the foundation to achieve its ambitious growth plans and
broaden and strengthen its offer across marketing and brand strategy, campaign development, inmarket
activation and digital delivery – with creativity at its heart.
Prof. Claire Thompson, multi award-winning CEO of Agility Life Sciences, has been recognised as one of the Top 10 Leaders in the field of small molecules on the 2022 Medicine Maker Power List.
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH A TOP 5 GLOBAL PHARMACEUTICAL COMPANY
Development of stable injectable high concentration formulations for its proprietary products
Cambridge, UK, 16 June 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with a top five global pharmaceutical company.
Leading contract research organisation (CRO) Cellomatics Biosciences has moved into new purpose-built premises in Nottingham in the wake of rising demand for its bespoke preclinical and early drug discovery phase laboratory services.
The ‘Invest USA’ events program is the launch pad that supports UK & European companies seeking to invest in the USA.
We assist in gaining direct access to the right independent advisors and partners to successfully enter the USA. We take out the hassle and support you every step of the way for sustainable success. A trusted, experienced team to assist you through your USA journey.
Each brief we receive is treated as a bespoke solution and our deliverables are customised
and tailored to your needs.
Cambridge, UK, 13 June 2022:
EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the appointment of Colin McCracken as Chief Executive Officer with immediate effect. Colin’s appointment will support the next phase of the Company’s development and the commercialisation of its semiconductor-based DNA synthesis platform.
Analysis Published by PrecisionLife Reveals Potential to Systematically Reposition Hundreds of Patented Drugs into New Indications to Address Unmet Medical Needs
AMSBIO has expanded its range of top quality, high-performance assay kits, antibodies, enzymes, and substrates for cellular metabolism research.
The Enterprise Strategy from Anglia Innovation Partnership LLP will kickstart investment into new businesses at Norwich Research Park.
Anglia Innovation Partnership LLP, the organisation that manages Norwich Research Park, has launched its Enterprise Strategy to kickstart investment into new businesses at the Park.